Figure 5.The distribution features and the OS KM curve of various clinicopathological factors in different risk groups. (A–C) Age, (D–F) Gender, (G–I) Grade, (J–L) Stage, (M–O) T.
Figure 5 — A pyrimidine metabolism-related signature for prognostic and immunotherapeutic response prediction in hepatocellular carcinoma by integrating analyses | Aging
